Physician profile
William L Madrid
NPI 1467419366
$5,508.19
in general payments reported to CMS, 2019-2025
30 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $357 · 2021: $736 · 2022: $813 · 2023: $716 · 2024: $857 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,651.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,102.80 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $871.11 | 2019-2025 | |
| Edwards Lifesciences Corporation | $500.87 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novo Nordisk INC | $487.45 | 2021-2025 | Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $474.39 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $269.34 | 2019-2025 | Impella |
| Pfizer INC. | $251.41 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $251.23 | 2019-2024 | Xarelto |
| Biotronik INC. | $238.34 | 2019-2022 | |
| Boston Scientific Corporation | $143.18 | 2019-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $128.10 | 2024-2025 | Verquvo, Capvaxive |
| Amgen INC. | $127.79 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $91.80 | 2020-2023 | Brilinta, Farxiga |
| Medtronic, INC. | $77.17 | 2022-2024 | Onyx Frontier |
| Medtronic Vascular, INC. | $49.02 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $48.97 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.68 | 2020-2024 | Jardiance |
| Amarin Pharma, INC. | $43.92 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.63 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $36.87 | 2019 | |
| Abbott Laboratories | $31.29 | 2023 | Cardiomems |
| Scpharmaceuticals INC. | $28.50 | 2024 | |
| Kestra Medical Technology Services, INC. | $25.51 | 2024 | Assure Wcd |
| Arbor Pharmaceuticals, INC. | $23.30 | 2019 | |
| Lilly USA, LLC | $22.94 | 2025 | Zepbound, Mounjaro |
| Actelion Pharmaceuticals US, INC. | $22.45 | 2024 | Uptravi, Opsumit |
| Cvrx, INC. | $18.24 | 2024 | Barostim Neo System |
| Angiodynamics, INC. | $18.18 | 2019 | |
| Ge Healthcare | $17.47 | 2020 | |
| Astellas Pharma US INC | $17.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Madrid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.